Elanix Biotechnologies AG

  • ISIN: DE000A0WMJQ4
  • Land: Deutschland

Nachricht vom 11.02.2019 | 07:58

Elanix Biotechnologies AG annuls profit guidance and preliminary earnings for FY 2017

Elanix Biotechnologies AG / Key word(s): Profit Warning/Change in Forecast
Elanix Biotechnologies AG annuls profit guidance and preliminary earnings for FY 2017

11-Feb-2019 / 07:58 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Elanix Biotechnologies AG annuls profit guidance and preliminary earnings for FY 2017

Berlin, 11 February 2019 - In the management report for the 2016 financial year, Elanix Biotechnologies AG ("Company") had amongst others reported that sales revenues of between EUR 300,000 and EUR 500,000 are expected in the 2017 financial year. Accordingly, revenues in the amount of EUR 328,148 were reported in the preliminary consolidated financial statements for FY 2017. Both reports have been prepared and signed during the tenure of former CEO Tomas J. Svoboda

Internal research of the new interim CEO has shown that this approach may be in breach of accounting rules and that the net assets, financial position and results of operations of the Company were described too positively. The Management Board therefore decided today to completely annul the earnings forecast as well as the preliminary earnings for the 2017 financial year. Currently, work is underway to prepare the annual financial statements for 2017.

Additionally, other mis-management has been detected concerning outstanding loans (associated with specific conditions along with various payments without contracts) which are still under scrutiny.

Lee Ann Laurent-Applegate


Elanix Biotechnologies AG
Lee Ann Laurent-Applegate
Tel: +41 (0)22 363 66 40

About Elanix

Elanix develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing.
Forward-looking statements

This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

11-Feb-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this


Media and Games Invest wächst dynamisch und profitabel

Innerhalb des Konzerns Media and Games Invest sind der wachstumsstarke Game-Publisher gamigo AG sowie Unternehmen aus dem dynamischen Bereich „Digital Media“ gebündelt. Der Wachstumskurs der Gesellschaft soll sowohl auf Basis eines anhaltenden anorganischen Wachstums sowie durch den Ausbau des bestehenden Geschäftes fortgesetzt werden. Im Rahmen unserer Initial-Coverage-Studie haben wir ein Kursziel von 1,90 € je Aktie ermittelt und vergeben das Rating KAUFEN..

News im Fokus

Vonovia SE: Erfolgreiches Pflichtangebot - Vonovia wird nach Settlement 94 Prozent der Hembla-Aktien halten (News mit Zusatzmaterial)

10. Dezember 2019, 16:06

Aktuelle Research-Studie

Achiko Ltd.

Original-Research: Achiko Ltd. (von Sphene Capital GmbH): Buy

12. Dezember 2019